ClinicalTrials.gg
Status unknownNCT04352153Updated Apr 20, 2020

Role of Uralyt-U in Patients With Hyperuricemia

An interventional study of Febuxostat and Uralyt-U in Uric Acid Stones and Hyperuricemia, sponsored by Ai Peng. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by Ai Peng · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing febuxostat in Hyperuricemia — 2 open to participants now, 4 under way, none of them phase 3. Febuxostat · Hyperuricemia.

Planned enrollment
14th of 26
102 · median 111
Started
2020
with 1 other
No phase
6 of 26
none open now
Registered
21st of 26
by date
Lead sponsor
1 of 26
Ai Peng

Among the 26 studies testing febuxostat in Hyperuricemia, this one is the 14th largest by planned enrollment, is one of 2 that started in 2020, is one of 6 with no phase, and was the 21st registered.

Hyperuricemia

240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.

Browse Hyperuricemia studies →

Open to participants now

2 of the 26 studies testing febuxostat in Hyperuricemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Hyperuricemia studies recruiting now, 9 (30%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing febuxostat in Hyperuricemia, or all of them as a file.
02

Study summary

The purpose of the study is to provide a more direct and objective basis for the widespread use of potassium sodium hydrogen citrate granules in the treatment of uric acid stones.

Read the detailed description

Hyperuricemia (HUA) is a common systemic metabolic disease. Its incidence is increasing year by year and more young people suffer from hyperuricemia. HUA can not only cause the onset of gouty arthritis, and then affect joint function, and even cause joint deformities. It can also cause damage to multiple organs such as the heart, brain, and kidney through multiple channels. Chronic kidney disease (CKD) refers to chronic kidney structural and dysfunction caused by various reasons. HUA is an independent risk factor that accelerates the progress of CKD. Studies have shown that lowering uric acid is another key treatment to delay the progress of CKD. A large number of studies have shown that the formation of uric acid crystals is the main mechanism of inducing renal injury.

In 2017, the "Multidisciplinary Expert Consensus for the Diagnosis and Treatment of Hyperuricemia-Related Diseases in China" recommended that patients with hyperuricemia receiving uric acid lowering drugs, especially those treated with uric acid excretion drugs and patients with uric acid nephrolithiasis, recommended that the pH of urine be adjusted during pH6.2 \~ 6.9 to increase the solubility of uric acid in urine. It is recommended to use sodium bicarbonate or potassium sodium citrate drugs to alkalinize urine, but it is not clear if there is any difference in the kinetic parameters of urine alkalinity, compliance rate of alkalinized urine and safety between sodium bicarbonate and potassium sodium citrate. No "head-to-head" clinical publications have been reported. This clinical trial was designed to evaluate the rate of alkalinization of urine, the therapeutic effect of renal lithiasis and adverse reactions between the sodium bicarbonate and potassium sodium hydrogen citrate granules in healthy people and patients with hyperuricemia and renal calculi (uric acid). This study provides a more direct and objective basis for the widespread use of potassium sodium hydrogen citrate granules in the treatment of uric acid stones.

03

Conditions studied

  • Uric Acid Stones
  • Hyperuricemia

Browse trials for

Keywords

  • Uric Acid Stones
  • Hyperuricemia
  • Uralyt-U
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-70 years old, male, outpatient or inpatient;
  • Acidic urinary stones
  • Serum uric acid value ≥480 µmol / L;
  • Other concomitant diseases (such as hypertension, hyperlipidemia, diabetes, etc.) are in a stable condition, and the dosage of other diseases is not changed during the test.
  • ≥30ml / min;

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Patients with acute or chronic renal failure ( \<30ml / min);
  • Patients with severe liver dysfunction (, AST≥70 IU);
  • In patients with uncontrolled hypertension, systolic blood pressure ≥160 and / or diastolic blood pressure ≥110mmHg;
  • In uncontrolled diabetic patients, fasting blood glucose is> 10mmol / L, and / or is ≥9%;
  • Patients that are taking atorvastatin, losartan, amlodipine, fenofibrate, pyrazinamide, tincture diuretics, thiazide diuretics, , agents and other drugs that affect uric acid excretion Drugs, those taking aspirin at a dose of> 325mg / day;
  • Cancer patients
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Single-use group

    Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

    Drug: Febuxostat

  • Experimental
    Research group

    Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

    Drug: Febuxostat · Drug: Uralyt-U

Interventions

  • Febuxostat is taken at a dose of 20 mg once a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

    Also known as: Uloric, Adenuric

  • DrugCitric AcidStudies of Citric AcidCitric Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Febuxostat is taken at a dose of 20 mg once a day, potassium sodium hydrogen citrate granules 7.5 g / day, 2.5 g / per time, three times a day. During the medication period, the urine pH of each subject is monitored and recorded in the morning, noon and night.

    Also known as: potassium sodium hydrogen citrate granules

06

What researchers measure

Primary outcomes

  1. Uric acid stones

    Uric acid stones will be estimated by dual-source CT examination

    Time frame: 3 months

  2. Uric acid stones

    Uric acid stones will be estimated by dual-source CT examination

    Time frame: 6 months

Secondary outcomes

  1. Blood uric acid

    Blood uric acid will be detected

    Time frame: 1 month

  2. Blood uric acid

    Blood uric acid will be detected

    Time frame: 3 months

  3. Blood uric acid

    Blood uric acid will be detected

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Department of Nephrolgoy, Shanghai 10th People's Hospital
    Shanghai, Shanghai 200072, China
    Recruiting
08

References and documents

Publications

  • Xue W, Cheng J, Zhao J, Wang L, Peng A, Liu X. Comparison potassium sodium hydrogen citrate with sodium bicarbonate in urine alkalization: a prospective crossover-controlled trial. Int Urol Nephrol. 2023 Jan;55(1):61-68. doi: 10.1007/s11255-022-03387-y. Epub 2022 Oct 19. PubMed 36261757 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Sep 2020, 5 months after the start.

Of 26 interventional studies with no phase under Hyperuricemia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 34. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2020
First posted
Apr 20, 2020
StartActual
Apr 1, 2020
Primary completionEst.
Sep 30, 2020
CompletionEst.
Oct 31, 2020
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04352153
Lead sponsor
Ai Peng
Responsible party
Ai Peng (Director of the department of Nephrology, Shanghai 10th people's hospital, Shanghai 10th People's Hospital) — Sponsor-investigator
First posted
Apr 20, 2020
Start date
Apr 1, 2020
Primary completion
Sep 30, 2020 (estimated)
Completion
Oct 31, 2020 (estimated)
Last update
Apr 20, 2020

Study contacts

Ai Peng, Ph.D., M.D.
Contact
pengai@tongji.edu.cn
86-21-66302524
Jiafen Cheng, M.D.
Contact
chengjiafen@tongji.edu.cn
86-21-66302527
Ai Peng, Ph.D., M.D.
principal investigator · Shanghai 10th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion